PRKAR2B Antibody

About the Target

PRKAR2B encodes the type II-beta regulatory subunit of the cAMP-dependent protein kinase A (PKA), a pivotal enzyme in the cAMP signaling pathway that regulates various cellular processes including metabolism, gene transcription, and cell proliferation. PRKAR2B contains an N-terminal dimerization/docking (D/D) domain that facilitates binding to A-kinase anchoring proteins (AKAPs) for precise subcellular localization, alongside two tandem cAMP-binding domains (A and B) that control allosteric activation of PKA by binding cAMP. Depending on the literature source, PRKAR2B may also be discussed as cAMP-dependent protein kinase type II-beta regulatory subunit.

Reported cellular context includes cell membrane, cytoplasm, and membrane, which can matter when signal is compared across treatments or changing cell states. Following PRKAR2B across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.

Research Context

PRKAR2B is commonly interpreted in the context of neuroscience and cell signaling research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cell membrane, cytoplasm, and membrane, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.

Consider these angles when interpreting target-level changes:

• apparent redistribution between cell membrane, cytoplasm, and membrane across matched conditions
• compartment-specific patterns relevant to neuronal polarity, transport, or synaptic context
• signal-dependent shifts after ligand, inhibitor, or growth-factor perturbation
• co-patterning with orthogonal markers and control conditions that clarify pathway state

Variant Considerations

If your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for PRKAR2B. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.

Standardize sampling time, control choice, and downstream analysis thresholds so apparent differences in PRKAR2B reflect biology rather than handling. When interpreting PRKAR2B, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.

For multi-run studies, a shared reference condition can keep PRKAR2B trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.